Company Details

  • Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

  •  [Hebei,China]
  • Business Type:Manufacturer , Trade Company
  • Main Mark: Americas , Asia , East Europe , Europe , North Europe , Oceania , Other Markets , West Europe , Worldwide
  • Exporter:81% - 90%
  • Certs:ISO9001, CCC, FDA, MSDS, FCC, REACH, RoHS
Inquiry Basket ( 0 )

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

Home > Industry Information > Pharmaceutical intermediate manufacture APIs Merchants in China
Industry Information

Pharmaceutical intermediate manufacture APIs Merchants in China

2019-02-21

"Over the past 60 years, the pharmaceutical industry has made remarkable achievements, but as we look ahead at the future, we must also see that China still has a long way to go before it becomes a strong country for pharmaceuticals. Brexpiprazole Intermediate, R Lorcaserin hydrochloride, Enzalutamide Intermediates, We must make even harder efforts to achieve it. The transition to a powerful pharmaceutical country must seize its own structural problems and take the road of independence, self-reliance and self-improvement.As an important component of the national economy, China’s pharmaceutical industry has experienced a turbulent history of 60 years with the growth of the Republic. In the past 60 years, there have been sighs, worries,

perplexities, inspirations, more boundless hopes, and brighter visions. Before the founding of New China, the pharmaceutical industry in China was in a poor and simple situation. It is capable of producing only a few types of APIs, with an annual output of only a few tons or so, and medical diagnosis and treatment equipment and equipment are almost entirely dependent on imports.Bayer AG first entered the Chinese market and established a company in Shanghai. Foreign companies have almost monopolized and monopolized the entire pharmaceutical industry, and there is no ethnic pharmaceutical company at all. In the days of political corruption, frequent wars, and lack of livelihood, lack of medical care and medicine are commonplace, not to mention health and well-being. After the founding of New China, the Chinese government attached great importance to the construction of the national health and health care industry and took various measures to promote the pharmaceutical industry. The rapid development has laid a relatively complete foundation for the pharmaceutical industry during the first five-year plan to the decade before the Cultural Revolution: North China Pharmaceutical Factory, Northeast Pharmaceutical Factory, Shandong Xinhua Pharmaceutical Factory, Taiyuan Pharmaceutical Factory, etc. have been established. A group of leading enterprises changed the situation in importing raw materials such as antibiotics, sulfonamides, antipyretic analgesics, vitamins, and anti-tuberculosis drugs; more than 60 pharmaceutical companies have completely transformed and established more than 20 technologically advanced chemicals. Pharmaceutical companies have been able to produce 375 APIs, with an annual output of nearly 20,000 tons, and chemical feedstocks have basically become self-sufficient; during this period, the Chinese medicine industry has also embarked on the road of industrialized production and established a batch of publicly owned proprietary Chinese medicine plants, which ended the dispersion. In the field of medical equipment, China has been able to produce general medical devices. The company has also produced more than 500 varieties of medical X-ray machines, ultrashort-wave electrotherapy machines, and specialist surgical instruments, and has made progress in the construction of drug laws and regulations. In 1965, the state issued the Administrative Measures for New Drug Products, etc. Since the reform and opening up, China's pharmaceutical industry has ushered in the spring of development, and its industry outlook has taken a new look.After China's accession to the WTO, China has changed from a policy-opening to an institutional-opening, and there has been a multinational game of competition in the new medical reform program. In the situation where the pace of transfer of pharmaceutical production centers to China is accelerating, China's pharmaceutical industry has maintained an average annual growth rate of over 20%. At present, it can produce more than 1,500 kinds of bulk drugs, ranking first in the world; 60 dosage forms for producing chemical preparations. More than 4500 varieties, the preparation capacity ranks in the forefront of the world; producing more than 300 kinds of various biological products, including more than 20 kinds of modern bio-engineering drugs; can produce including X-ray tomography imaging devices, nuclear magnetic resonance devices, etc. 47 categories 3000 kinds Medical device products. China has become a major supplier of pharmaceutical giants and international small and medium-sized medical device products. Some authoritative agencies predict that in 2011, China will become the world's third largest pharmaceutical market with huge market opportunities and broad production potential, making China an internationally-focused focus. Needless to say, the past 60 years have made remarkable achievements in the pharmaceutical industry. However, while looking ahead at the future, we must also see that China still has a long way to go from a pharmaceutical power and must make even harder efforts. From a horizontal perspective, the performance of Chinese companies participating in international competition is still not satisfactory. The main gaps are: First, in the division of labor of the global pharmaceutical market, China is still at the low end of the main dependence on raw material exports, exports of low value-added products. About 70% of the total export value, the proportion of high value-added products such as Chinese and Western pharmaceutical preparations, biochemical drugs, and hospital diagnosis and treatment equipment accounts for a relatively small proportion; second, compared with international advanced enterprises, many pharmaceutical companies in China are only satisfied to do Products, but seldom involved in the market, the international market's strategic planning capabilities and marketing capabilities are still inadequate, brand awareness, intellectual property rights awareness and global corporate citizenship needs to be improved; Third, the vicious competition between the industry, the market order The lack of it has led to the internationalization of domestic competition and the internalization of international competition, which has greatly weakened the bargaining power of the entire industry. Many companies have fallen under the foot of their “brothers” in the fierce international competition. Fourth, with the continuous exposure of drug quality incidents in recent years, the international reputation of Chinese-made pharmaceutical products faces new challenges. How to take effective measures to create a healthy and sound institutional environment for the majority of companies has become a core issue for enhancing the international competitiveness of the industry. From a longitudinal perspective, although China established a good foundation for the pharmaceutical industry as early as several decades ago, since the reform and opening up, compared with industries such as communications, home appliances, automobiles, and machinery manufacturing, the pace of development of the pharmaceutical industry has clearly Slowly, it mainly manifests itself in the following aspects: First, the institutional obstacles have not been fundamentally resolved. At present, there are as many as a dozen national ministries and commissions that can implement management in the pharmaceutical industry. There are many governments and difficulties in coordination, resulting in slow decision-making. Realize centralized and effective management in the true sense; Second, China's pharmaceutical market is open to all-round foreign investment, and it has not achieved the ideal effect of market-for-technology change. Foreign technology spillovers can only become “Nanke's dream” in many cases; Many corporate concepts are outdated and satisfy the status quo. There is no long-term vision for development. The phenomenon of low-level and repeated construction is serious. The degree of industrial concentration is very low. A group of enterprise groups with core competitive advantages has not yet been formed. Fourth, there is a lack of potential for industrial development. In particular, the current practice of patent protection objectively leads to a general shortage of R&D investment by pharmaceutical companies. The average investment only accounts for about 3% of sales. The absolute and relative numbers of scientific research personnel are also obviously insufficient. Up till now, there is not yet a group of brand products that can be called out loudly. There is no one between the government, research institutes, and the market. The effective government, production, learning, research, and trade chain, and the fact that enterprises are the mainstay of innovation, has not yet taken shape. There is a mismatch between R&D and output. For the pharmaceutical industry with real and potential advantages, its problems are both common and individual. Although it takes a long process to solve the structural problems, a core premise must not be ignored. That is, to realize the transition from a big pharmaceutical country to a powerful pharmaceutical country, we must seize our own structural problems and take the initiative. The path of self-reliance and self-reliance. In this process, we must deepen international competition and cooperation to achieve low-end learning and high-end learning. We must take advantage of the situation and become unfavorable in order to prepare for the leap-forward development of the pharmaceutical industry.

Communicate with Supplier?Supplier
Lily Ms. Lily
What can I do for you?
Contact Supplier